Free cash flow remains consistently negative with a quarterly burn of $18.4 million in 2026Q1, reflecting a structural dependence on cash reserves given the minimal $19,000 in quarterly capital expenditures.
| Cash from Operations | -65.41M | -60.08M | -59.08M | -40.68M | -97.21M | -12.45M | -98.8M | -67.67M | -37.65M | -16.38M | -3.31M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -27.58% | -1.69% | -45.23% | 58.15% | -680.54% | 87.4% | -46.01% | -79.74% | -129.81% | -394.33% | - |
| Net Income | -83.49M | -74.15M | -57.98M | -42.82M | -32.18K | -8.93M | -119.71M | -72.97M | -46.36M | -18.65M | -4.66M |
| Depreciation & Amortization | 1.74M | 1.38M | 1.65M | 1.48M | 1.01K | 364K | 1.21M | 850K | 380K | 45K | 0 |
| Stock-Based Compensation | 12.6M | 10.5M | 3.49M | 1.12M | 1.12K | 639K | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 35.47M | 2.27M | 4.04M | 127K | -89.78M | -6.45M | 15.46M | 6.63M | 2.9M | 549K | 463K |
| Working Capital Changes | 81K | -70K | -10.28M | -584K | -7.4M | 1.92M | 4.24M | -2.18M | 4.18M | 1.59M | 710K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -1.47M | 116K | -1.42M | -165K | -3.1M | 1.45M | -881K | 1.03M | 2.02M | 176K | 177K |
| Cash from Investing | -102K | -138K | -156K | -279K | -267K | -2.12M | -1.18M | -1.58M | -1.83M | -383K | -24K |
| Capital Expenditures | -254K | -208K | -156K | -279K | -267K | -2.12M | -1.18M | -1.58M | -1.83M | -383K | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 110K | 70K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 42K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | -3.92M | 173.35M | 171.71M | 33.75M | 262K | 41.42M | 172.62M | 129.99M | 160.29M | 17.37M | 8.7M |
| Debt Issued (Net) | -371K | -489K | -475K | -499K | -393K | 3.61M | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | -3.52M | 174.33M | 94.6M | 34.13M | 262K | 37.81M | 172.62M | 129.99M | 160.29M | 17.41M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -27K | -485K | 77.59M | 121K | 393K | 2K | 0 | 0 | 0 | -44K | 8.7M |
| Net Change in Cash | -69.45M | 113.04M | 112.47M | -7.2M | -96.72M | 26.84M | 72.64M | 60.74M | 120.34M | 606K | 5.36M |
| Free Cash Flow | -65.66M | -60.29M | -59.24M | -40.96M | -97.47M | -14.58M | -99.98M | -69.25M | -39.48M | -16.77M | -3.31M |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | -4.11% | -1.77% | -44.62% | 57.98% | -568.74% | 85.42% | -44.37% | -75.41% | -135.49% | -405.88% | - |
| FCF per Share | -3.50 | -3.29 | -4.01 | -11.03 | -26.74 | -4.08 | -33.14 | -30.29 | -19.93 | -8.40 | -1.66 |
| FCF Conversion (FCF/Net Income) | 0.79x | 0.81x | 1.02x | 0.95x | 3.02x | 1.40x | 0.83x | 0.93x | 0.81x | 0.88x | 0.71x |
| Interest Paid | 0 | 0 | 107K | 152K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Clinical trial execution failure
As reported in quarterly financial statements, Tectonic Therapeutic's operating cash flow consistently tracks below net income, with an OCF/NI ratio of 0.73 in 2026Q1, highlighting the structural disconnect between accounting losses and the actual cash required to sustain the company's intensive clinical development programs.
The persistent gap between net income and operating cash flow suggests that non-cash expenses and working capital fluctuations are not sufficient to offset the heavy cash burn required for R&D. Investors should monitor this conversion ratio, as it indicates that the company's cash-based operational reality is more demanding than the accrual-based net income figures might imply.
Based on the company's reported figures, free cash flow has remained consistently negative, with a quarterly burn of $18.4 million in 2026Q1, underscoring the firm's total dependence on its existing cash reserves to fund the advancement of its GEODe platform and clinical pipeline.
The lack of positive free cash flow is expected for a clinical-stage biotech, yet the trend shows no signs of stabilization as clinical trial costs mount. This trajectory warrants further investigation into the company's ability to manage its burn rate effectively as it moves into more expensive, later-stage clinical trials.
According to recent SEC filings, Tectonic Therapeutic maintains an extremely low capital intensity, with CapEx totaling only $19,000 in 2026Q1, which reflects the company's asset-light model that prioritizes outsourced laboratory and clinical execution over heavy investment in internal manufacturing or physical infrastructure.
The negligible CapEx suggests that the company is not currently burdened by significant maintenance or growth-related capital requirements. This allows management to direct the vast majority of its available liquidity toward R&D, though it also implies a reliance on third-party capacity that could introduce operational bottlenecks.
As indicated in quarterly data, stock-based compensation has reached as high as $5.1 million in 2025Q4, which effectively masks the true cash cost of talent acquisition and retention required to support the company's complex protein engineering and clinical development objectives.
While SBC is a non-cash expense, it represents a significant dilution risk that investors should account for when evaluating the company's long-term capital structure. The reliance on equity-based incentives may help preserve cash in the short term, but it may also lead to substantial shareholder dilution as the company scales its headcount.
Quick answers to the most common questions about buying TECX stock.
Tectonic Therapeutic, Inc. (TECX) generated $-60.1M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Tectonic Therapeutic, Inc. (TECX) reported negative free cash flow of $60.3M in 2025, indicating capital requirements exceeded cash from operations.
Tectonic Therapeutic, Inc. (TECX) spent $0.2M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.